Aligos Therapeutics (NASDAQ:ALGS) & LadRx (OTCMKTS:CYTR) Head-To-Head Analysis

Aligos Therapeutics (NASDAQ:ALGS) and LadRx (OTCMKTS:CYTR) are both small-cap medical companies, but which is the better business? We will compare the two companies based on the strength of their risk, analyst recommendations, earnings, profitability, institutional ownership, dividends and valuation.

Risk and Volatility

Aligos Therapeutics has a beta of 2.19, suggesting that its stock price is 119% more volatile than the S&P 500. Comparatively, LadRx has a beta of 1.96, suggesting that its stock price is 96% more volatile than the S&P 500.

Insider & Institutional Ownership

60.4% of Aligos Therapeutics shares are held by institutional investors. Comparatively, 0.1% of LadRx shares are held by institutional investors. 16.5% of Aligos Therapeutics shares are held by company insiders. Comparatively, 12.8% of LadRx shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a stock will outperform the market over the long term.

Profitability

This table compares Aligos Therapeutics and LadRx’s net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
Aligos Therapeutics	-476.77%	-86.51%	-61.08%
LadRx	N/A	-67.61%	-45.39%

Analyst Ratings

This is a summary of current ratings and recommmendations for Aligos Therapeutics and LadRx, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Aligos Therapeutics	0	1	2	0	2.67
LadRx	0	0	0	0	N/A

Aligos Therapeutics presently has a consensus price target of $4.00, indicating a potential upside of 361.47%.

Earnings and Valuation

This table compares Aligos Therapeutics and LadRx’s gross revenue, earnings per share and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Aligos Therapeutics	$13.91 million	2.71	-$96.05 million	($1.91)	-0.45
LadRx	N/A	N/A	-$6.70 million	($0.15)	N/A

LadRx has lower revenue, but higher earnings than Aligos Therapeutics. Aligos Therapeutics is trading at a lower price-to-earnings ratio than LadRx, indicating that it is currently the more affordable of the two stocks.

About Aligos Therapeutics

Aligos Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses to develop novel therapeutics to address unmet medical needs in viral and liver diseases. Its lead drug candidate is ALG-097558, which is in Phase I clinical trial for the treatment of coronavirus; and ALG-000184, a capsid assembly modulator, which is completed Phase 1b clinical trial to treat chronic hepatitis B (CHB). The company also develops ALG-055009, a small molecule THR-ß agonist that is in the Phase 2 clinical trial for the treatment of non-alcoholic steatohepatitis (NASH). In addition, it develops siRNA drug candidate, ALG-125755, which is in Phase I clinical trial for the treatment of CHB. Aligos Therapeutics, Inc. has entered into license and collaboration agreements with Luxna Biotech Co., Ltd. to develop and commercialize products containing oligonucleotides targeting hepatitis B virus genome; Emory University to provide hepatitis B virus capsid assembly modulator technology; research, licensing, and commercialization agreement with Katholieke Universiteit Leuven to develop coronavirus protease inhibitors; and Merck to discover, research, optimize, and develop oligonucleotides directed against a NASH, as well as a research collaboration and development agreement with Xiamen Amoytop Biotech Co., Ltd. to research and develop oligonucleotide compounds for the treatment of liver diseases.. The company was incorporated in 2018 and is headquartered in South San Francisco, California.

About LadRx

LadRx Corporation, a biopharmaceutical company, engages in the discovery and development of therapeutics to treat patients with cancer. The company's advanced drug conjugate, aldoxorubicin that is in late-stage clinical trials is a version of anti-cancer drug doxorubicin. Its pre-clinical therapeutics comprise linker activated drug releases 7, 8, 9, and 10 targeted against cancer The company was formerly known as CytRx Corporation and changed its name to LadRx Corporation in September 2022. LadRx Corporation was incorporated in 1985 and is headquartered in Los Angeles, California.